CC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Chemours is not a good buy right now for a beginner long-term investor with $50,000-$100,000, and I would not chase it after the recent drop. The stock has improving analyst targets and some supportive option sentiment, but the current technical setup is weak, the latest quarter showed thin profitability, and there is no strong proprietary buy signal. My direct view: hold off for now rather than buy today.
CC closed at 22.38 after a sharp -5.32% regular-session decline, which is bearish in the near term. MACD histogram is -0.373 and expanding negatively, confirming downside momentum. RSI_6 at 27.63 is near oversold, but not yet a clean reversal signal. The moving-average structure is still constructive with SMA_5 > SMA_20 > SMA_200, so the longer trend is not broken. Price is below the pivot at 25.648 and below resistance levels, with nearby support at 23.165 and deeper support at 21.631. The setup suggests pressure in the short run, and the stock trend model implies a potential short-term bounce, but still a weaker one-month profile.
Analysts have been steadily raising price targets, with Mizuho up to $30, Truist up to $30, UBS up to $29, and RBC up to $26, all with positive ratings. The latest Q1 2026 report showed 22% year-over-year net sales growth, which is a meaningful top-line improvement. Chemours also announced a quarterly dividend of $0.0875, which supports shareholder returns. Options positioning is constructive, and the stock has bullish moving averages on the chart.
The stock sold off sharply in the latest session, showing poor immediate momentum. Q1 2026 still produced a net loss of $29 million, EPS of -0.19, and gross margin fell to 15.5%, so profitability remains weak despite revenue growth. Revenue only increased 0.95% in the financial snapshot, which is not strong enough to suggest a broad operational breakout. Alta Fundamental Advisers LLC reduced its stake by 175,000 shares, and hedge funds/insiders are both neutral. No AI Stock Picker or SwingMax signal is present today.
In Q1 2026, Chemours posted revenue of $1.381 billion, with the company also noting a 22% year-over-year increase in net sales. However, profitability remains soft: net income was -$29 million, EPS was -0.19, and gross margin declined to 15.5%. That means the latest quarter had better sales but weaker margins and ongoing losses. For a long-term beginner investor, the growth trend is positive on revenue but not yet strong enough on earnings quality.
Analyst sentiment has improved over the last month, with multiple target increases and continued Buy/Outperform ratings. Mizuho, Truist, UBS, and RBC all raised targets, generally into the high-$20s to $30 range. Wall Street pros see upside from Chemours’ advantaged TiO2 footprint, diversification into refrigerants, and pricing leverage from supply tightness. The pro view is positive, but there is still some caution from firms like Goldman Sachs, JPMorgan, and Morgan Stanley, which maintain Neutral/Equal Weight-type stances. Overall, the analyst trend is constructive but not unanimous.
